N-Myc Promotes Therapeutic Resistance Development of Neuroendocrine Prostate Cancer by Differentially Regulating MiR-421/ATM Pathway

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2019 Jan 19

PMID 30657058

Citations 58

Authors

Yu Yin

Lingfan Xu

Yan Chang

Tao Zeng

Xufeng Chen

Aifeng Wang

Jeff Groth

Wen-Chi Foo

Chaozhao Liang

Hailiang Hu

Jiaoti Huang

Affiliations

Soon will be listed here.

Abstract

Background: MYCN amplification or N-Myc overexpression is found in approximately 40% NEPC and up to 20% CRPC patients. N-Myc has been demonstrated to drive disease progression and hormonal therapeutic resistance of NEPC/CRPC. Here, we aim to identify the molecular mechanisms underlying the N-Myc-driven therapeutic resistance and provide new therapeutic targets for those N-Myc overexpressed NEPC/CRPC.

Methods: N-Myc overexpressing stable cell lines for LNCaP and C4-2 were generated by lentivirus infection. ADT-induced senescence was measured by SA-β-gal staining in LNCaP cells in vitro and in LNCaP xenograft tumors in vivo. Migration, cell proliferation and colony formation assays were used to measure the cellular response after overexpressing N-Myc or perturbing the miR-421/ATM pathway. CRISPR-Cas9 was used to knock out ATM in C4-2 cells and MTS cell viability assay was used to evaluate the drug sensitivity of N-Myc overexpressing C4-2 cells in response to Enzalutamide and ATM inhibitor Ku60019 respectively or in combination.

Results: N-Myc overexpression suppressed ATM expression through upregulating miR-421 in LNCaP cells. This suppression alleviated the ADT-induced senescence in vitro and in vivo. Surprisingly, N-Myc overexpression upregulated ATM expression in C4-2 cells and this upregulation promoted migration and invasion of prostate cancer cells. Further, the N-Myc-induced ATM upregulation in C4-2 cells rendered the cells resistance to Enzalutamide, and inhibition of ATM by CRISPR-Cas9 knockout or ATM inhibitor Ku60019 re-sensitized them to Enzalutamide.

Conclusions: N-Myc differentially regulating miR-421/ATM pathway contributes to ADT resistance and Enzalutamide resistance development respectively. Combination treatment with ATM inhibitor re-sensitizes N-Myc overexpressed CRPC cells to Enzalutamide. Our findings would offer a potential combination therapeutic strategy using ATM kinase inhibitor and Enzalutamide for the treatment of a subset of mCRPC with N-Myc overexpression that accounts for up to 20% CRPC patients.

Citing Articles

LncRNA PCAT6 promotes progression and metastasis of colonic neuroendocrine carcinoma MAPK pathway.

Wang F, Mu H, Wang C, Tang Y, Si M, Peng J World J Gastrointest Oncol. 2025; 17(2):96230.

PMID: 39958556 PMC: 11755991. DOI: 10.4251/wjgo.v17.i2.96230.

MicroRNAs as Promising Therapeutic Agents Against Prostate Cancer Resistant to Castration-Where Are We Now?.

Ferreira M, Morais M, Medeiros R, Teixeira A Pharmaceutics. 2024; 16(11).

PMID: 39598472 PMC: 11597238. DOI: 10.3390/pharmaceutics16111347.

Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling.

Tabibian M, Moghaddam F, Motevaseli E, Ghafouri-Fard S Cell Commun Signal. 2024; 22(1):504.

PMID: 39420406 PMC: 11484332. DOI: 10.1186/s12964-024-01833-1.

Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets.

Jiang J, Han D, Wang J, Wen W, Zhang R, Qin W MedComm (2020). 2024; 5(10):e761.

PMID: 39372390 PMC: 11450264. DOI: 10.1002/mco2.761.

circTP63 promotes prostate cancer progression via miR-421/VAMP associated protein A axis.

Xu J, Xu S, Liu W, Chen J, Cai L, Zhuang W J Cancer. 2024; 15(16):5451-5461.

PMID: 39247600 PMC: 11375539. DOI: 10.7150/jca.99561.

References

Sun M, Guo X, Qian X, Wang H, Yang C, Brinkman K . Activation of the ATM-Snail pathway promotes breast cancer metastasis. J Mol Cell Biol. 2012; 4(5):304-15. PMC: 3464396. DOI: 10.1093/jmcb/mjs048. View

Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H . SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. Eur Urol. 2016; 71(1):68-78. DOI: 10.1016/j.eururo.2016.04.028. View

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L . N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016; 30(4):563-577. PMC: 5540451. DOI: 10.1016/j.ccell.2016.09.005. View

Watson P, Arora V, Sawyers C . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15(12):701-11. PMC: 4771416. DOI: 10.1038/nrc4016. View

Hu H, Du L, Nagabayashi G, Seeger R, Gatti R . ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A. 2010; 107(4):1506-11. PMC: 2824372. DOI: 10.1073/pnas.0907763107. View

Beltran H, Rickman D, Park K, Suk Chae S, Sboner A, MacDonald T . Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2012; 1(6):487-95. PMC: 3290518. DOI: 10.1158/2159-8290.CD-11-0130. View

Park J, Lee J, Witte O, Huang J . FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod Pathol. 2017; 30(9):1262-1272. PMC: 6330177. DOI: 10.1038/modpathol.2017.44. View

Mosquera J, Beltran H, Park K, MacDonald T, Robinson B, Tagawa S . Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013; 15(1):1-10. PMC: 3556934. DOI: 10.1593/neo.121550. View

Beltran H, Prandi D, Mosquera J, Benelli M, Puca L, Cyrta J . Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016; 22(3):298-305. PMC: 4777652. DOI: 10.1038/nm.4045. View

10.

Zhang W, Liu B, Wu W, Li L, Broom B, Basourakos S . Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2017; 24(3):696-707. PMC: 5823274. DOI: 10.1158/1078-0432.CCR-17-1872. View

11.

Day R, Snow A, Panganiban R . Radiation-induced accelerated senescence: a fate worse than death?. Cell Cycle. 2014; 13(13):2011-2. PMC: 4111686. DOI: 10.4161/cc.29457. View

12.

Ewald J, Desotelle J, Church D, Yang B, Huang W, Laurila T . Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo. Prostate. 2012; 73(4):337-45. PMC: 4753826. DOI: 10.1002/pros.22571. View

13.

Haffner M, Aryee M, Toubaji A, Esopi D, Albadine R, Gurel B . Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010; 42(8):668-75. PMC: 3157086. DOI: 10.1038/ng.613. View

14.

Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C . Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006; 444(7119):638-42. DOI: 10.1038/nature05327. View

15.

Crona D, Whang Y . Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. Cancers (Basel). 2017; 9(6). PMC: 5483886. DOI: 10.3390/cancers9060067. View

16.

Matsuoka S, Ballif B, Smogorzewska A, McDonald 3rd E, Hurov K, Luo J . ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007; 316(5828):1160-6. DOI: 10.1126/science.1140321. View

17.

Brockmann M, Poon E, Berry T, Carstensen A, Deubzer H, Rycak L . Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell. 2013; 24(1):75-89. PMC: 4298657. DOI: 10.1016/j.ccr.2013.05.005. View

18.

Akamatsu S, Wyatt A, Lin D, Lysakowski S, Zhang F, Kim S . The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015; 12(6):922-36. DOI: 10.1016/j.celrep.2015.07.012. View

19.

Varambally S, Dhanasekaran S, Zhou M, Barrette T, Kumar-Sinha C, Sanda M . The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-9. DOI: 10.1038/nature01075. View

20.

Tan H, Sood A, Rahimi H, Wang W, Gupta N, Hicks J . Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2013; 20(4):890-903. PMC: 3931005. DOI: 10.1158/1078-0432.CCR-13-1982. View